Literature DB >> 17192069

Non-invasive imaging of carcinogen-induced early neoplasia using ultrahigh-resolution optical coherence tomography.

Michael J Cobb1, Yuchuan Chen, S Lawrence Bailey, Christopher J Kemp, Xingde Li.   

Abstract

BACKGROUND AND
OBJECTIVE: Improved diagnostics capable of non-invasive detection of early stage carcinogenesis would benefit basic research, and potentially aid in clinical cancer diagnosis and management. The two-stage carcinogenesis protocol is widely used for studying the multi-stage nature of tumor development in mice and provides insight into tumor development in other animal models and humans. The objective of this study was to investigate the feasibility of non-invasive optical coherence tomography (OCT) for in vivo imaging of microanatomical changes in the epidermis and dermis during early carcinogenesis using a mouse skin model.
MATERIALS AND METHODS: 10 NIH mice were treated with DMBA and TPA following the well-established two-stage carcinogenesis protocol. OCT imaging of treated skin from live mice was performed at five time points (Week 4-8) after tumor initiation to reveal the structural changes in the epidermis and dermis associated with the earliest, premalignant stages of tumor development. OCT images were compared with histology findings. In addition, OCT signals were quantitatively analyzed to evaluate tissue optical property changes during early carcinogenesis.
RESULTS: Early structural changes in the epidermis, dermis and hair follicles during carcinogenesis were clearly delineated in vivo using OCT. OCT images correlated well with histological findings. Quantitative OCT signal analysis revealed a statistically significant change in the extinction coefficient for untreated (40.5 +/- 17.0 mm(-1)) and treated (9.6 +/- 3.6 mm(-1)) mouse epidermis (P < 0.005). The dermis extinction coefficient for the treated mouse skin (3.7 +/- 0.9 mm(-1)) was lower than the untreated one (4.7 +/- 1.6 mm(-1)), but was not statistically significant (P > 0.10). Furthermore, the papilloma extinction coefficient (2.9 +/- 0.3 mm(-1)) was significantly lower than the extinction coefficient for the treated epidermis (P < 0.005) and dermis (P < 0.01).
CONCLUSION: OCT is a viable tool for assessing the earliest stages of carcinogenesis and has potential for early detection of neoplasia in skin, as well as in epithelial linings of other organs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17192069     DOI: 10.3233/cbm-2006-23-408

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  5 in total

1.  Quantitative tool for rapid disease mapping using optical coherence tomography images of azoxymethane-treated mouse colon.

Authors:  Amy M Winkler; Photini F S Rice; Rebekah A Drezek; Jennifer K Barton
Journal:  J Biomed Opt       Date:  2010 Jul-Aug       Impact factor: 3.170

Review 2.  Intraoperative imaging techniques for glioma surgery.

Authors:  Tomas Garzon-Muvdi; Carmen Kut; Xingde Li; Kaisorn L Chaichana
Journal:  Future Oncol       Date:  2017-08-10       Impact factor: 3.404

3.  Detection of human brain cancer infiltration ex vivo and in vivo using quantitative optical coherence tomography.

Authors:  Carmen Kut; Kaisorn L Chaichana; Jiefeng Xi; Shaan M Raza; Xiaobu Ye; Elliot R McVeigh; Fausto J Rodriguez; Alfredo Quiñones-Hinojosa; Xingde Li
Journal:  Sci Transl Med       Date:  2015-06-17       Impact factor: 17.956

4.  In vivo assessment of vascular-targeted photodynamic therapy effects on tumor microvasculature using ultrahigh-resolution functional optical coherence tomography.

Authors:  Defu Chen; Wu Yuan; Hyeon-Cheol Park; Xingde Li
Journal:  Biomed Opt Express       Date:  2020-07-15       Impact factor: 3.562

5.  Stimuli-disassembling gold nanoclusters for diagnosis of early stage oral cancer by optical coherence tomography.

Authors:  Chang Soo Kim; Dominique Ingato; Petra Wilder-Smith; Zhongping Chen; Young Jik Kwon
Journal:  Nano Converg       Date:  2018-01-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.